Company news

Revolution Medicines, Inc. news in 2025

Revolution Medicines, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

December 17, 2025

Delphia Therapeutics Appoints Leading Cancer Expert Steve Kelsey, M.D., to Board of Directors

December 9, 2025

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

November 4, 2025

Revolution Medicines to Participate in November 2025 Investor Conferences

November 3, 2025

Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

October 28, 2025

Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

October 26, 2025

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

October 21, 2025

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

October 15, 2025

Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

September 28, 2025

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

September 9, 2025

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

August 5, 2025

Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025

July 29, 2025

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

July 23, 2025

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

July 22, 2025

Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

July 8, 2025

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

June 29, 2025

Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

June 29, 2025

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

June 23, 2025

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

June 22, 2025

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

May 13, 2025

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

May 6, 2025

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

April 29, 2025

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

April 26, 2025

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

March 31, 2025

Revolution Medicines to Participate in April 2025 Investor Conferences

March 30, 2025

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

February 25, 2025

Revolution Medicines to Participate in March 2025 Investor Conferences

February 23, 2025

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

February 18, 2025

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

January 28, 2025

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Calls in 2025

Decks in 2025